According to the report by Expert Market Research (EMR), the global actinic keratosis treatment market reached a value of USD 7.1 billion in 2022. Aided by the escalating prevalence of actinic keratosis and the expansion of treatment options across healthcare sectors, the market is projected to further grow at a CAGR of 4.2% between 2023 and 2031 to reach a value of USD 10.2 billion by 2031.
Actinic keratosis, also known as solar keratosis, is a skin condition characterised by rough, scaly patches on the skin’s surface, primarily caused by prolonged exposure to the sun. The disorder is precancerous, meaning it can lead to skin cancer if left untreated. Various treatments for actinic keratosis include topical medications, photodynamic therapy, chemical peels, laser resurfacing, and cryotherapy. These treatments play a critical role in preventing the progression of the disorder to squamous cell carcinoma, a common and potentially dangerous form of skin cancer.
The rising incidence of actinic keratosis is primarily driving the global actinic keratosis treatment market size. The need for efficient therapies is growing as people become more aware of the risks of excessive sun exposure and the possibility that actinic keratosis could develop into skin cancer. Also contributing to the rise in demand for treatment options is the ageing population, which is more susceptible to the ailment due to a weakening immune system and accumulative sun exposure.
The broadening applications of actinic keratosis treatments in various healthcare settings are significantly fuelling the actinic keratosis treatment market development. These procedures are increasingly used in dermatology as a part of a whole skin care routine for patients who have suffered serious sun damage. Similar to this, in the cosmetics sector, certain procedures like chemical peels and laser resurfacing are used to improve general skin look in addition to treating actinic keratosis, thereby increasing the demand.
Moreover, the continuous research and development activities aimed at formulating more effective and patient-friendly treatment options are pushing the actinic keratosis treatment market forward. With the rise in the development of novel drug delivery systems and the advent of targeted therapies, the field of actinic keratosis treatment has witnessed several advancements, further fuelling the actinic keratosis treatment market expansion.
Market Segmentation
The market can be divided based on treatment type, end user, treatment channel, distribution channel, and region.
Market Breakup by Treatment Type
- Topical Treatments
- Fluorouracil
- Imiquimod
- Diclofenac
- Ingenol mebutate
- Photodynamic Therapy (PDT)
- Cryotherapy
- Chemical Peels
- Laser Therapy
- Others
Market Breakup by End User
- Hospitals
- Dermatology Clinics
- Ambulatory Surgical Centres
- Homecare
- Others (Research Institutes, Academic Institutes, etc.)
Market Breakup by Treatment Channel
- Public
- Private
Market Breakup by Distribution Channel
- Direct Tenders
- Retail Sales
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Competitive Landscape
The EMR report looks into the market shares, plant turnarounds, capacities, investments, and acquisitions and mergers, among other major developments, of the global actinic keratosis treatment companies. Some of the major key players explored in the report by Expert Market Research are as follows:
- Galderma S.A.
- LEO Pharma
- Bausch Health Companies Inc.
- Almirall, S.A.
- Sun Pharmaceutical Industries Ltd.
- Perrigo Company plc.
- GlaxoSmithKline plc.
- Novartis AG
- Valeant Pharmaceuticals International, Inc.
- Teva Pharmaceutical Industries Ltd.
